CAJ | 학술논문

目的：探讨紫杉醇脂质体联合顺铂治疗晚期胃癌的临床疗效及不良反应，为临床诊疗提供参考。方法35例初治的晚期胃癌患者均给予紫杉醇脂质体135mg/m2，第1天静脉滴注3h,顺铂25mg/m2静脉滴注，d1～3,每周期21d，至少连用2周期。按RECIST1.0标准对治疗效果及不良反应进行评价。结果完全缓解2例，部分缓解16例，病变稳定4例，疾病进展13例，客观有效率为51.43%，疾病控制率为62.86%；疾病中位进展时间为7.4个月，中位生存时间为15.3个月；血液学毒性是其最常见的不良反应，白细胞Ⅲ～Ⅳ度降低发生率为14.29%，无化疗相关死亡病例；其余胃肠道反应、脱发等均以Ⅰ～Ⅱ度为主。结论紫杉醇脂质体联合顺铂治疗晚期胃癌临床疗效好，不良反应小，值得进一步扩大样本量进行深入研究。
목적：탐토자삼순지질체연합순박치료만기위암적림상료효급불량반응，위림상진료제공삼고。방법35례초치적만기위암환자균급여자삼순지질체135mg/m2，제1천정맥적주3h,순박25mg/m2정맥적주，d1～3,매주기21d，지소련용2주기。안RECIST1.0표준대치료효과급불량반응진행평개。결과완전완해2례，부분완해16례，병변은정4례，질병진전13례，객관유효솔위51.43%，질병공제솔위62.86%；질병중위진전시간위7.4개월，중위생존시간위15.3개월；혈액학독성시기최상견적불량반응，백세포Ⅲ～Ⅳ도강저발생솔위14.29%，무화료상관사망병례；기여위장도반응、탈발등균이Ⅰ～Ⅱ도위주。결론자삼순지질체연합순박치료만기위암림상료효호，불량반응소，치득진일보확대양본량진행심입연구。
Objective To explore the clinical efficacy of liposomal paclitaxel in combination with cisplatin in patients with advanced gastric cancer and adverse reactions and to provide reference for clinical diagnosis.Methods 35 cases of previously untreated patients with advanced gastric cancer were treated with liposomal paclitaxel 135mg/m2,the first day intravenous infusion 3h;Cisplatin 25mg/m2 itravenous infused,d1-3,21d per period,at least 2 cycles.Treatment effects and adverse reactions were evaluated by RECIST1.0 standard.Results Two cases were complete remission,16 cases were partial remission,4 cases were stable,13 cases were disease progression, and objective response rate was 51.43%, disease control rate was 62.86%;The median time to progression of disease was 7.4 months,and the median survival time was 15.3 months; Hematologic toxicity was the most common adverse reactions,WBCⅢ-Ⅳ degrees lower incidence was 14.29%,and no chemotherapy-related deaths; The remaining gastrointestinal reactions,alopecia degree were mainⅠ-Ⅱ.Conclusion Liposomal paclitaxel plus cisplatin therapy for advanced gastric cancer shows good clinical efficacy,with less adverse reactions,worthy of further expanding the sample size in-depth study.